| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442791 | European Journal of Cancer | 2014 | 11 Pages |
Abstract
The addition of sorafenib to gemcitabine did not demonstrate improved efficacy in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might benefit from combined treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Moehler, A. Maderer, C. Schimanski, S. Kanzler, U. Denzer, F.T. Kolligs, M.P. Ebert, A. Distelrath, M. Geissler, J. Trojan, M. Schütz, L. Berie, C. Sauvigny, F. Lammert, A. Lohse, M.M. Dollinger, U. Lindig, E.M. Duerr, M. Woerns,